ZiconotideSpecialist pain medicine
Ziconotide is a synthetic version of a peptide originally identified in cone-snail venom. Its medical use is highly specialised: pain treatment delivered into the fluid around the spinal cord.
What is Ziconotide?
Ziconotide is a synthetic peptide derived from a molecule discovered in cone-snail venom. It is a specialist, non-opioid medicine for severe refractory pain, delivered into the fluid around the spinal cord.
How it works
It blocks N-type calcium channels involved in releasing chemical messengers between nerve cells. This can reduce spinal pain signalling without activating opioid receptors.
Effects studied
Severe refractory pain
An intrathecal trial studied pain that had not responded adequately to other treatments. Its findings concern this specialist delivery method and patient population, not ordinary muscle soreness or a topical product. 1
Evidence: Controlled clinical trial; route-specific evidence.
What does the evidence show?
The archive includes a controlled trial of intrathecal ziconotide for severe refractory pain. The route, specialist monitoring and neurological risks are central to interpreting that evidence.
From a venom signal to a medicine
Pain messages pass between nerve cells using chemical messengers. Ziconotide blocks N-type calcium channels involved in that release. Interrupting this step can reduce pain signalling without acting through the opioid receptors targeted by morphine. Its origin in venom is a history of drug discovery, not a reason to use venom products.
Why the delivery method matters
Ziconotide is delivered into cerebrospinal fluid through a carefully managed system, a route called intrathecal administration. This reaches the relevant spinal targets. Evidence for that treatment cannot establish the same effect from swallowing, injecting under the skin or applying an unregulated preparation.
Who was studied
The retained trial studied severe pain that had not responded adequately to other approaches. Lower pain scores need to be weighed against effects on thinking, balance and daily function. The study concerns specialist treatment; it does not establish suitability for ordinary backache or exercise soreness. 1
The important trade-off
Confusion, dizziness and psychiatric or neurological effects require close attention. A pump and catheter also introduce device-related complications, including infection. The archived product information is relevant background; a current local prescribing document and specialist assessment are needed for any clinical decision. 2
Safety & status
Confusion, dizziness and psychiatric or neurological effects require specialist monitoring. The pump and catheter introduce additional risks, including infection. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is ziconotide an opioid?
No. It acts on calcium channels rather than opioid receptors, although a different mechanism does not make it a low-risk painkiller.
Why is it delivered into spinal fluid?
Intrathecal delivery gives access to the spinal targets. Evidence for that route cannot be applied to oral, topical or under-the-skin preparations.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Ziconotide: paper 10.1001/jama.291.1.63 Research reference · Retained archive reference; not independently checked for this draft.
- Ziconotide: www.drugs.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.